Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics.

Blower S, Wald A, Gershengorn H, Wang F, Corey L.

J Infect Dis. 2004 Nov 1;190(9):1610-7. Epub 2004 Sep 30.

2.

Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines.

Schwartz EJ, Bodine EN, Blower S.

Hum Vaccin. 2007 Nov-Dec;3(6):231-8.

PMID:
17881889
3.

Genital herpes infection: a review.

Brugha R, Keersmaekers K, Renton A, Meheus A.

Int J Epidemiol. 1997 Aug;26(4):698-709. Review.

4.

Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?

Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ.

Antiviral Res. 2004 Aug;63 Suppl 1:S3-9. Review.

PMID:
15450380
6.

Modelling the genital herpes epidemic.

Blower S.

Herpes. 2004 Aug;11 Suppl 3:138A-146A. Review.

PMID:
15319083
7.

HSV shedding.

Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ.

Antiviral Res. 2004 Aug;63 Suppl 1:S19-26. Review.

PMID:
15450382
8.

An update on short-course episodic and prevention therapies for herpes genitalis.

Corey L, Bodsworth N, Mindel A, Patel R, Schacker T, Stanberry L.

Herpes. 2007 Jun;14 Suppl 1:5A-11A. Review.

PMID:
17877886
9.

Herpes simplex virus type 2 transmission: risk factors and virus shedding.

Wald A.

Herpes. 2004 Aug;11 Suppl 3:130A-137A. Review.

PMID:
15319082
10.
11.

Herpes simplex virus: the importance of asymptomatic shedding.

Koelle DM, Wald A.

J Antimicrob Chemother. 2000 Apr;45 Suppl T3:1-8. Review.

12.

Dynamic modeling of herpes simplex virus type-2 (HSV-2) transmission: issues in structural uncertainty.

Foss AM, Vickerman PT, Chalabi Z, Mayaud P, Alary M, Watts CH.

Bull Math Biol. 2009 Apr;71(3):720-49. doi: 10.1007/s11538-008-9379-1. Epub 2009 Feb 14.

PMID:
19219511
13.

Reducing the risk of transmitting genital herpes: advances in understanding and therapy.

Leone P.

Curr Med Res Opin. 2005 Oct;21(10):1577-82. Review.

PMID:
16238897
14.
15.

A model of the transmission and control of genital herpes.

Newton EA, Kuder JM.

Sex Transm Dis. 2000 Aug;27(7):363-70.

PMID:
10949427
16.

Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines.

Schwartz EJ, Blower S.

J Infect Dis. 2005 May 15;191(10):1734-46. Epub 2005 Apr 13.

17.

Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.

Kim HN, Wald A, Harris J, Almekinder J, Heitman C, Corey L.

Sex Transm Dis. 2008 Feb;35(2):124-8.

PMID:
17921912
18.

Strategies to control the genital herpes epidemic.

Schinazi RB.

Math Biosci. 1999 Jul;159(2):113-21.

PMID:
10414029
19.

Antivirals in the prevention of genital herpes.

Au E, Sacks SL.

Herpes. 2002 Dec;9(3):74-7. Review.

PMID:
12470605
20.

[An epidemiological model of genital herpes for assessment of potential impact of therapy and prophylaxis: application to France].

Boƫlle PY, Fagnani F, Valleron AJ, Detournay B, El Hasnaoui A, Halioua B, Nicolas JC.

Ann Dermatol Venereol. 2004 Jan;131(1 Pt 1):17-26. French.

PMID:
15041839
Items per page

Supplemental Content

Write to the Help Desk